Interestingly, serum levels of soluble LOX-1 were reported to be elevated significantly in patients with LV systolic dysfunction and hypertrophy, and were correlated with the decrease in EF in patients with ACS [17, 19, 23]. The gene discussed is OLR1; the disease is cardiac hypertrophy.